stockportfolio.pro
Vor Biopharma Inc. (VOR)
Healthcare · Biotechnology · NasdaqGS
Vor Biopharma Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-43.34M | $-68.90M | $-92.09M | $-117.86M | $-116.91M | $-695.98M |
| Net margin | — | — | — | — | — | — |
Source: Vor Biopharma Inc. SEC filings (10-K).
Explore 6 years of Vor Biopharma Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track VOR in your portfolio →
Vor Biopharma Inc. financial history by metric
About Vor Biopharma Inc.
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Vor Biopharma Inc. — frequently asked questions
What is Vor Biopharma Inc.'s revenue?
Vor Biopharma Inc. (VOR) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Vor Biopharma Inc. profitable?
No — VOR reported a net loss of $-695.98M in fiscal 2025.
What is VOR's P/E ratio?
Vor Biopharma Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Vor Biopharma Inc. have?
As of fiscal year 2025, VOR carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Vor Biopharma Inc.'s market cap?
Vor Biopharma Inc. (VOR) has a market capitalization of about $752.91M, based on the latest data in our nightly-refreshed cache.
When does Vor Biopharma Inc.'s fiscal year end?
VOR's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Vor Biopharma Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.